CTOs on the Move

Obsidian Therapeutics

www.obsidiantx.com

 
Obsidian Therapeutics is pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian`s programs apply our cytoDriveTM technology in cell and gene therapy products to control expression of proteins for enhanced therapeutic efficacy, including our lead program cytoTIL15 engineered to make TILs more effective for more patients. Our aspirations are high, and we`re built to deliver – well-funded with blue chip investors, engaged field-leading advisors, strong partnerships with industry leaders, and a highly experienced, dynamic, innovative and collaborative team, collectively focused on delivering transformative therapies in areas of greatest clinical need. Located in the ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.obsidiantx.com
  • 1030 Massachusetts Avenue Suite 400
    Cambridge, MA USA 02138
  • Phone: 781.806.6245

Executives

Name Title Contact Details

Funding

Obsidian Therapeutics raised $49.5M on 12/06/2017

Similar Companies

Sionna Therapeutics

We are a life sciences company that is building on over a decade of extensive research on the genetic mutations associated with cystic fibrosis.

Nurse On Call

Nurse On Call is a Naples, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ABI Inc

ABI Inc is a Bedford, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioTheryX

BioTheryX is a clinical-stage biopharmaceutical company focused on restoring protein homeostasis through protein modulation, including protein degradation as well as multi-kinase inhibition, to develop treatments that extend and improve the quality-of-life of patients with life-threatening diseases.

Nurix Therapeutics

Nurix Therapeutics discovers drugs that harness the body`s natural process to control protein levels. Our drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases. Our focus is on developing drugs to treat cancer including novel, small molecule immuno-oncology agents.